162 related articles for article (PubMed ID: 38467839)
1. Lipidomics reveals new lipid-based lung adenocarcinoma early diagnosis model.
Sun T; Chen J; Yang F; Zhang G; Chen J; Wang X; Zhang J
EMBO Mol Med; 2024 Apr; 16(4):854-869. PubMed ID: 38467839
[TBL] [Abstract][Full Text] [Related]
2. Lipid metabolism gene-wide profile and survival signature of lung adenocarcinoma.
Li J; Li Q; Su Z; Sun Q; Zhao Y; Feng T; Jiang J; Zhang F; Ma H
Lipids Health Dis; 2020 Oct; 19(1):222. PubMed ID: 33050938
[TBL] [Abstract][Full Text] [Related]
3. Transcriptomic landscape based on annotated clinical features reveals PLPP2 involvement in lipid raft-mediated proliferation signature of early-stage lung adenocarcinoma.
Wang Y; Miao Z; Qin X; Yang Y; Wu S; Miao Q; Li B; Zhang M; Wu P; Han Y; Li B
J Exp Clin Cancer Res; 2023 Nov; 42(1):315. PubMed ID: 37996944
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
5. Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis.
Zhu M; Zeng Q; Fan T; Lei Y; Wang F; Zheng S; Wang X; Zeng H; Tan F; Sun N; Xue Q; He J
Front Immunol; 2022; 13():783495. PubMed ID: 35222371
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma.
Wang Y; Xu J; Fang Y; Gu J; Zhao F; Tang Y; Xu R; Zhang B; Wu J; Fang Z; Li Y
Front Immunol; 2022; 13():950001. PubMed ID: 36091041
[TBL] [Abstract][Full Text] [Related]
7. Plasma extracellular vesicle microRNA profiling and the identification of a diagnostic signature for stage I lung adenocarcinoma.
Gao S; Guo W; Liu T; Liang N; Ma Q; Gao Y; Tan F; Xue Q; He J
Cancer Sci; 2022 Feb; 113(2):648-659. PubMed ID: 34837453
[TBL] [Abstract][Full Text] [Related]
8. Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma.
Bao X; Shi R; Zhao T; Wang Y
J Mol Med (Berl); 2020 Jun; 98(6):805-818. PubMed ID: 32333046
[TBL] [Abstract][Full Text] [Related]
9. A two-circular RNA signature as a noninvasive diagnostic biomarker for lung adenocarcinoma.
Liu XX; Yang YE; Liu X; Zhang MY; Li R; Yin YH; Qu YQ
J Transl Med; 2019 Feb; 17(1):50. PubMed ID: 30777071
[TBL] [Abstract][Full Text] [Related]
10. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
Wu C; Rao X; Lin W
Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
[TBL] [Abstract][Full Text] [Related]
11. A combination of four serum miRNAs for screening of lung adenocarcinoma.
Wang J; Zhang C; Peng X; Liu K; Zhao L; Chen X; Yu H; Lai Y
Hum Cell; 2020 Jul; 33(3):830-838. PubMed ID: 32388809
[TBL] [Abstract][Full Text] [Related]
12. Lung cancer scRNA-seq and lipidomics reveal aberrant lipid metabolism for early-stage diagnosis.
Wang G; Qiu M; Xing X; Zhou J; Yao H; Li M; Yin R; Hou Y; Li Y; Pan S; Huang Y; Yang F; Bai F; Nie H; Di S; Guo L; Meng Z; Wang J; Yin Y
Sci Transl Med; 2022 Feb; 14(630):eabk2756. PubMed ID: 35108060
[TBL] [Abstract][Full Text] [Related]
13. Secreted proteins MDK, WFDC2, and CXCL14 as candidate biomarkers for early diagnosis of lung adenocarcinoma.
Li J; Li J; Hao H; Lu F; Wang J; Ma M; Jia B; Zhuo M; Wang J; Chi Y; Zhai X; Wang Y; Wu M; An T; Zhao J; Yang F; Wang Z
BMC Cancer; 2023 Jan; 23(1):110. PubMed ID: 36721112
[TBL] [Abstract][Full Text] [Related]
14. Gut mycobiome as a potential non-invasive tool in early detection of lung adenocarcinoma: a cross-sectional study.
Liu Q; Zhang W; Pei Y; Tao H; Ma J; Li R; Zhang F; Wang L; Shen L; Liu Y; Jia X; Hu Y
BMC Med; 2023 Oct; 21(1):409. PubMed ID: 37904139
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Signature and Discrimination Signature of Lung Adenocarcinoma based on Pyroptosis-Related Genes.
Li GS; Lu HP; Gao L; Li JD; He RQ; Zhou HF; Chen SW; Liu J; Fu ZW; Kong JL; Zeng JH; He J; Chen G
Comb Chem High Throughput Screen; 2023; 26(2):347-361. PubMed ID: 35593363
[TBL] [Abstract][Full Text] [Related]
16. Transcriptomic analysis identifies CYP27A1 as a diagnostic marker for the prognosis and immunity in lung adenocarcinoma.
Yin Y; He M; Huang Y; Xie X
BMC Immunol; 2023 Oct; 24(1):37. PubMed ID: 37817081
[TBL] [Abstract][Full Text] [Related]
17. Construction and experimental validation of an acetylation-related gene signature to evaluate the recurrence and immunotherapeutic response in early-stage lung adenocarcinoma.
Wang H; Lu X; Chen J
BMC Med Genomics; 2022 Dec; 15(1):254. PubMed ID: 36503492
[TBL] [Abstract][Full Text] [Related]
18. Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma.
Song Q; Shang J; Yang Z; Zhang L; Zhang C; Chen J; Wu X
J Transl Med; 2019 Mar; 17(1):70. PubMed ID: 30832680
[TBL] [Abstract][Full Text] [Related]
19. High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma.
Luo R; Zhong P; Li X; Cai J; Tao Y; Xiong B; Zheng H; Zhang Z; Tang L; Yao J; Li Y; Shi Y; Han X
Cancer Epidemiol Biomarkers Prev; 2023 May; 32(5):726-738. PubMed ID: 36857775
[TBL] [Abstract][Full Text] [Related]
20. A ten-gene signature-based risk assessment model predicts the prognosis of lung adenocarcinoma.
Jiang H; Xu S; Chen C
BMC Cancer; 2020 Aug; 20(1):782. PubMed ID: 32819300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
